PL1737438T3 - Pochodne Alfa-aminoamidu użyteczne do leczenia zespołu niespokojnych nóg - Google Patents

Pochodne Alfa-aminoamidu użyteczne do leczenia zespołu niespokojnych nóg

Info

Publication number
PL1737438T3
PL1737438T3 PL05736365T PL05736365T PL1737438T3 PL 1737438 T3 PL1737438 T3 PL 1737438T3 PL 05736365 T PL05736365 T PL 05736365T PL 05736365 T PL05736365 T PL 05736365T PL 1737438 T3 PL1737438 T3 PL 1737438T3
Authority
PL
Poland
Prior art keywords
treatment
alpha
derivatives useful
restless legs
legs syndrome
Prior art date
Application number
PL05736365T
Other languages
English (en)
Inventor
Claudia Besana
Elena Barbanti
Emanuela Izzo
Florian Thaler
Ruggero Fariello
Patricia Salvati
Luca Benatti
Original Assignee
Newron Pharm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Newron Pharm Spa filed Critical Newron Pharm Spa
Publication of PL1737438T3 publication Critical patent/PL1737438T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
PL05736365T 2004-04-22 2005-04-19 Pochodne Alfa-aminoamidu użyteczne do leczenia zespołu niespokojnych nóg PL1737438T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04009532A EP1588704A1 (en) 2004-04-22 2004-04-22 Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
PCT/EP2005/004166 WO2005102300A1 (en) 2004-04-22 2005-04-19 α-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME AND ADDICTIVE DISORDERS
EP05736365A EP1737438B1 (en) 2004-04-22 2005-04-19 Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome

Publications (1)

Publication Number Publication Date
PL1737438T3 true PL1737438T3 (pl) 2009-01-30

Family

ID=34924693

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05736365T PL1737438T3 (pl) 2004-04-22 2005-04-19 Pochodne Alfa-aminoamidu użyteczne do leczenia zespołu niespokojnych nóg
PL07022078T PL1900362T3 (pl) 2004-04-22 2005-04-19 Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL07022078T PL1900362T3 (pl) 2004-04-22 2005-04-19 Pochodne alfa-aminoamidu użyteczne w leczeniu zaburzeń uzależnieniowych

Country Status (25)

Country Link
US (2) US8445513B2 (pl)
EP (3) EP1588704A1 (pl)
JP (1) JP5020069B2 (pl)
KR (2) KR101195819B1 (pl)
CN (1) CN1942179B (pl)
AT (2) ATE405256T1 (pl)
AU (1) AU2005235428B2 (pl)
BR (2) BR122020004541B1 (pl)
CA (1) CA2563674C (pl)
CY (2) CY1108494T1 (pl)
DE (2) DE602005025941D1 (pl)
DK (2) DK1900362T3 (pl)
ES (2) ES2357559T3 (pl)
HR (2) HRP20080593T3 (pl)
IL (1) IL178732A (pl)
ME (2) ME01219B (pl)
MX (1) MXPA06012163A (pl)
NO (2) NO337900B1 (pl)
NZ (1) NZ550664A (pl)
PL (2) PL1737438T3 (pl)
PT (2) PT1900362E (pl)
RS (2) RS50667B (pl)
RU (1) RU2403030C2 (pl)
SI (2) SI1900362T1 (pl)
WO (1) WO2005102300A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
IL160523A0 (en) 2001-09-03 2004-07-25 Newron Pharm Spa PHARMACEUTICAL COMPOSITION COMPRISING GABAPENTIN OR AN ANALOGUE THEREOF AND AN alpha-AMINOAMIDE AND ITS ANALGESIC USE
EP1438956A1 (en) * 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AU2004266494B2 (en) * 2003-08-25 2010-04-08 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
ATE471147T1 (de) * 2004-09-10 2010-07-15 Newron Pharm Spa Verwendung von (r)-(halogenbenzyloxy)-benzylamino-propanamiden als natrium- und/oder calciumkanal- selektive modulatoren
US20060173074A1 (en) * 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
EP1963280B1 (en) * 2005-12-22 2015-10-28 Newron Pharmaceuticals S.p.A. 2-phenylethylamino derivatives as calcium and/or sodium channel modulators
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1870097A1 (en) 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
HUE030233T2 (en) 2006-06-19 2017-04-28 Newron Pharm Spa High purity 2- [4- (3- and 2-fluorobenzyloxy) benzylamino] propanamides for use as medicaments and pharmaceutical compositions containing them
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
PT2155663T (pt) 2007-06-15 2018-01-16 Newron Pharm Spa Derivados de 2-[2-(fenil)etilamino]alcanamida substituídos e sua utilização como moduladores dos canais de sódio e/ou de cálcio
CA2936209C (en) 2007-12-11 2020-02-11 Newron Pharmaceuticals S.P.A. Process for the production of 2-[4-(3- or 2-fluorobenzyloxy)benzylamino]propanamides with high purity degree
BRPI0821026A2 (pt) * 2007-12-19 2015-06-16 Newron Pharmaceutical S P A Derivados de alfa-minoamidas úteis no tratamento de transtornos psiquiátricos
EP2314569A1 (en) 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
JP5808392B2 (ja) 2010-04-27 2015-11-10 ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー ラルフィナミドメタンスルホネート塩またはそのｒ−エナンチオマーの製造方法
US11278651B2 (en) * 2018-10-17 2022-03-22 Gambro Lundia Ab Membrane and device for treating restless leg syndrome
CN114667963B (zh) * 2020-12-24 2024-04-26 中国科学院脑科学与智能技术卓越创新中心 一种非人灵长类动物药物成瘾性评估的装置

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1140748A (en) 1966-06-23 1969-01-22 Ici Ltd New carboxylic acid derivatives
US4049663A (en) * 1972-06-06 1977-09-20 Allen & Hanburys Limited Ethylene diamine derivatives
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
EP0331620B1 (de) * 1988-03-01 1993-08-11 Birkmayer, Walther, Prof. Dr. Mittel zur Behandlung des Parkinson-Syndroms
IL94466A (en) * 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
EP0520325A1 (de) * 1991-06-28 1992-12-30 F.Hoffmann-La Roche & Co. Aktiengesellschaft Verwendung von Monoaminoxidase-B-Hemmern zur Verhütung und Behandlung von Entzugserscheinungen nach Alkohol- und Drogenmissbrauch
GB9306886D0 (en) 1993-04-01 1993-05-26 Erba Carlo Spa Substituted (arylakoxybenzyl) aminopropanamide derivatives and process for their preparation
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
MX9709112A (es) * 1995-05-26 1998-02-28 Pfizer Combinacion para el tratamiento de parkinsonismo que contienen antagonistas selectivos de n-metil-d-aspartato.
WO1997000511A1 (de) 1995-06-17 1997-01-03 Baumann Guenter Scheibenkörper
GB9515411D0 (en) 1995-07-27 1995-09-27 Pharmacia Spa N-(4-substituted-benzyl)-2-aminolactam derivatives
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
DE19701619B4 (de) * 1997-01-17 2007-10-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Pramipexol zur Behandlung des restless legs syndroms
GB9727521D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Substituted 2-benzylamino-2-phenyl-acetamide compounds
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
WO1999035215A2 (en) 1998-01-12 1999-07-15 Deborah Wenzel An additive composition also used as a fuel composition comprising water soluble alcohols
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
AU1359801A (en) * 1999-11-05 2001-06-06 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
AU2080201A (en) 1999-12-10 2001-06-18 University Of Cincinnati, The Treatment of addiction disorders
US20020019421A1 (en) * 2000-07-05 2002-02-14 Roni Biberman Compositions and therapy for substance addiction
EP1406631A4 (en) * 2001-06-13 2005-03-23 Univ Michigan DOPAMIN RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREFOR
EA009372B1 (ru) * 2002-05-29 2007-12-28 Ф. Хоффманн-Ля Рош Аг N-ациламинобензольные производные в качестве селективных ингибиторов моноаминооксидазы в
AU2003279409A1 (en) 2002-06-24 2004-01-06 Rockwool International A/S Process and apparatus for controlling mineral wool production using a cascade rotor
US6900354B2 (en) * 2002-07-15 2005-05-31 Hoffman-La Roche Inc. 3-phenyl-propionamido, 3-phenyl-acrylamido and 3-phenyl-propynamido derivatives
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
JP2005060370A (ja) * 2003-07-25 2005-03-10 Kyowa Hakko Kogyo Co Ltd 医薬組成物
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1588704A1 (en) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders

Also Published As

Publication number Publication date
DE602005009162D1 (de) 2008-10-02
EP1900362B1 (en) 2011-01-12
SI1737438T1 (sl) 2008-12-31
IL178732A0 (en) 2007-05-15
BRPI0509976B8 (pt) 2021-05-25
NO20064732L (no) 2006-11-22
NO337900B1 (no) 2016-07-04
HRP20080593T3 (en) 2008-12-31
AU2005235428A1 (en) 2005-11-03
US8697738B2 (en) 2014-04-15
DE602005025941D1 (de) 2011-02-24
RU2403030C2 (ru) 2010-11-10
HRP20110230T1 (hr) 2011-04-30
IL178732A (en) 2013-01-31
BRPI0509976A (pt) 2007-10-16
RS50667B (sr) 2010-06-30
CY1108494T1 (el) 2014-04-09
DK1737438T3 (da) 2008-12-08
HK1099216A1 (en) 2007-08-10
ME01219B (me) 2013-06-20
US8445513B2 (en) 2013-05-21
CA2563674C (en) 2012-12-18
NO338870B1 (no) 2016-10-31
EP1737438A1 (en) 2007-01-03
PT1900362E (pt) 2011-03-09
KR101195819B1 (ko) 2012-11-05
NO20150971L (no) 2006-11-22
NZ550664A (en) 2010-08-27
DK1900362T3 (da) 2011-05-09
AU2005235428B2 (en) 2010-03-18
CY1111656T1 (el) 2015-10-07
WO2005102300A1 (en) 2005-11-03
PT1737438E (pt) 2008-12-22
BRPI0509976B1 (pt) 2020-10-06
ATE405256T1 (de) 2008-09-15
SI1900362T1 (sl) 2011-03-31
BR122020004541B1 (pt) 2021-11-09
EP1900362A3 (en) 2009-04-01
JP5020069B2 (ja) 2012-09-05
ME02324B (me) 2016-06-20
ES2357559T3 (es) 2011-04-27
US20130217747A1 (en) 2013-08-22
KR20120028399A (ko) 2012-03-22
EP1588704A1 (en) 2005-10-26
ES2313330T3 (es) 2009-03-01
CN1942179A (zh) 2007-04-04
PL1900362T3 (pl) 2011-06-30
RU2006137079A (ru) 2008-04-27
US20070203182A1 (en) 2007-08-30
ATE494890T1 (de) 2011-01-15
KR20070042914A (ko) 2007-04-24
RS51791B (sr) 2011-12-31
MXPA06012163A (es) 2007-01-17
CA2563674A1 (en) 2005-11-03
EP1900362A2 (en) 2008-03-19
CN1942179B (zh) 2010-08-11
JP2007533691A (ja) 2007-11-22
KR101238377B1 (ko) 2013-03-04
EP1737438B1 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
PL1737438T3 (pl) Pochodne Alfa-aminoamidu użyteczne do leczenia zespołu niespokojnych nóg
LUC00217I2 (pl)
ZA200706691B (en) Process for preparing lansoprazole
IL208607A0 (en) Improved nanobodiestm for the treatment of aggregation-mediated disorders
EP1853539A4 (en) HONOKIOL DERIVATIVES TO TREAT PROLIFERATIVE DISEASES
UA89812C2 (ru) Замещенные пиридинильные и пиримидинильные производные, которые применяют как модуляторы метаболизма и для лечения ассоциированных с ним расстройств
ZA200903952B (en) Bicyclic compounds and use as antidiabetics
IL191283A (en) Compositions for treating eye irregularities
IL180736A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
IL188390A0 (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
ZA200700011B (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders diseases associated with angiogenesis
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders
IL191750A0 (en) Imidazole derivatives for the treatment of gastrointestinal disorders
PL1907374T3 (pl) Pochodne benzylopiperazyny użyteczne do leczenia zaburzeń układu pokarmowego
PT2366393E (pt) Roflumilaste para o tratamento da hipertensão pulmonar
IL185653A (en) Antibodies that call for the 1-kim salt region
PL1879585T3 (pl) Zastosowanie pochodnych pirymidyloaminobenzamidowych do leczenia mastocytozy układowej
ZA200800409B (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
EP1937242A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES AND ADDITIVES
PL1961423T3 (pl) Zastosowanie pneumocytów typu II w leczeniu chorób płuc związanych z zwłóknieniem płuc
HK1118542A (en) Imidazolyl-pyrimidine compounds for use in the treatment of proliferative disorders
IL188104A0 (en) Compounds useful for treating bipolar disorders
WO2006060202A3 (en) Imidazole derivatives for the treatment of psychiatric disorders